The case for & against
Bull & Bear analysis
Gentherm Inc. (NASDAQ: THRM) is a leader in thermal management technologies, primarily catering to the automotive sector while also expanding into adjacent markets, including medical applications and home comfort solutions. With a strong focus on innovation and customer engagement, Gentherm is strategically positioned to capitalize on the growing demand for climate control and comfort solutions across various industries.
Bull says
- ↑2025 revenue $1.5 B (+2.9% YoY), guidance at $1.5–1.6 B for 2026
- ↑Q3 new business awards of $745 M, bringing YTD total to $1.8 B
- ↑Operating cash flow of $117 M in 2025; net leverage at 0.3x
- ↑FDA-cleared Thermafix launch set for Q3 2026, targeting medical market
- ↑Diversification into home, office, medical to add $50–100 M by 2028
- ↑Strong financial health, positive analyst revisions, low leverage
Bear says
- ↓Adjusted EBITDA margin down to 11.7% amid material cost inflation
- ↓Merger with Modine brings integration and standalone division risks
- ↓Global auto production may decline ~3% in 2026, pressuring revenues
- ↓Q2–Q3 2026 margins expected to compress under inflationary headwinds
- ↓Missed adjacent-market targets could weaken investor confidence
- ↓Weak profitability metrics and high short interest signal caution
Investment themes with THRM
Car manufacturers and auto parts suppliers
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- We received a significant award from Ford on their F-Series platform, which reinforces that GenTherm thermal and pneumatic products are not just focused on the luxury vehicle segment but they are becoming the customer standard and applicable to large volume platforms.
- reinforces that gen therm thermal and pneumatic products are not just focused on the luxury vehicle segment but they are becoming the customer standard and applicable to large volume platforms.
- In the second quarter, automotive climate and comfort solutions outperformed actual light vehicle production in our key markets by 10 basis points, excluding FX.
Bear points
- we did have strong outperformance in North America and Europe, weighed down by underperformance in Asia, where our share does not currently represent the market.
- Second quarter revenue decreased 0.2% compared to the same period last year. Foreign exchange adjusted revenues decreased 1.6%.
- Medical revenue decreased 3.8% year-over-year, or 4.8%, excluding the impact of FX.